In the preceding three months, 4 analysts have released ratings for Regenxbio (NASDAQ:RGNX), presenting a wide array of perspectives from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $36.5, a high estimate of $50.00, and a low estimate of $18.00. Experiencing a 17.05% decline, the current average is now lower than the previous average price target of $44.00.

Investigating Analyst Ratings: An Elaborate Study

In examining recent analyst actions, we...